This Week's Poll

At the recent BioPartner Forum it was stated the internal market is insufficient for a UK Life Science company to develop a technology, product or service at a rate that will return investor value. Do you

Supported by Medilink UK

Bio and medtech start ups - Tony Davis of - MedilinkWM - 13:53:01pm Jul-20th

I was recently at the BioPartner Annual Dinner, at which several companies commented on how US universities allow time for the maturing of technologies that they have nurtured. whilst UK universities are pressurised by the finance framework, into making to narrow a market valuation and then having to internationalise to soon. Other pressures to internationalise to soon were considered to be due to the poor adoption rates for technology in the home market

Agree/Disagree + add comment
 
 
t